What Фламадекс Treats: Main Uses and Benefits

Фламадекс is applied across therapeutic domains involving symptoms related to physical discomfort, inflammation, or systemic imbalance, where supportive symptom management is appropriate. The medication is commonly used for the management of acute symptoms associated with pain of mild to moderate intensity, generally applied when supportive symptomatic assistance is needed. The application of the medicine is relevant for acute musculoskeletal pain, dysmenorrhoea, and dental pain.

The medication is relevant for conditions characterized by periods of heightened symptoms related to the musculoskeletal system, such as sprains, strains, lumbago, sciatica, and active flare-ups of osteoarthritis or rheumatoid arthritis, as well as sudden events like renal colic and discomfort following acute procedures. It assists with maintaining a sense of stability when symptoms are more noticeable, supporting general well-being during symptomatic phases.

---

Quick Facts: Therapeutic Benefit

Property	Description
Symptom Axes	Symptoms related to physical discomfort, inflammation, and systemic imbalance
Condition Categories	Conditions involving episodic or fluctuating manifestations (e.g., painful periods, flare-ups)
Patient Benefit	Supports the patient during difficult episodes by easing distress and assists with maintaining functional stability

Regulatory References

1. HPRA Summary of Product Characteristics

Who can and cannot use Фламадекс?

This section describes the population eligibility for Фламадекс (Dexketoprofen) as defined in official regulatory documents, without providing usage instructions or medical advice.

Eligibility Status	Official Regulatory Rule
Allowed Population	Adults for symptomatic relief.
Contraindicated Populations	Children and Adolescents (under 18 years); Third Trimester of Pregnancy and Lactation; patients with known hypersensitivity to any NSAID.

Contraindications (Absolute Prohibition) The medicine is prohibited for patients with active peptic ulcer/GI bleeding or a history of the same, severe heart failure, or haemorrhagic diathesis/coagulation disorders. It must not be used in individuals with severe hepatic impairment (Child-Pugh Class C) or moderate to severe renal impairment (creatinine clearance le 59 mL/min).

Restricted/Conditional Use Elderly patients and those with mild hepatic or renal impairment (CCl 60-89 mL/min) are eligible but must commence treatment at a reduced initial dose (e.g., 50 mg total daily dose) and be closely monitored. Use during the first and second trimesters of pregnancy is also restricted and requires careful necessity assessment.

Interactions with other medicines and products

This section summarizes documented drug interactions based on official regulatory sources. It is critical to note that the product's effectiveness can be altered by co-administered agents, and certain combinations carry a heightened risk of adverse effects.

Agents Affecting Absorption

Medicines and supplements containing polyvalent cations (e.g., iron supplements, calcium supplements) or antacids (e.g., containing aluminum or magnesium) can significantly reduce the absorption of this product from the digestive tract. To minimize this effect, a strict time separation of at least four hours is required between administration of this product and these agents. Bile acid sequestrants also require this temporal separation.

Clinically Significant Interactions

• Oral Anticoagulants: This product may potentiate the effects of oral anticoagulants, increasing the risk of bleeding. Close and frequent monitoring of coagulation parameters (e.g., prothrombin time or INR) is necessary upon initiation or change of dose.
• Antidiabetic Agents: In diabetic patients, this product may increase the dosage requirements for both insulin and oral antidiabetic medicines. Blood glucose levels must be monitored carefully.
• Sympathomimetic Amines: The co-administration of this product with sympathomimetic amines is documented to increase the risk of serious cardiac toxicity and is strongly discouraged due to this serious health concern.
• Estrogens/Oral Contraceptives: Medicines containing estrogens (such as oral contraceptives) may increase the dosage requirement for this product by altering the binding proteins in the blood.

How Фламадекс Works — Mechanism of Action

Targeting Inflammatory Mediator Production

The mechanism is defined by the dexketoprofen component acting as an inhibitor of Cyclooxygenase (COX-1 and COX-2) enzymes. This interaction blocks the Arachidonic Acid Cascade, thereby suppressing the synthesis of local chemical messengers known as prostaglandins. The reduction of these pro-inflammatory mediators, such as prostaglandin E2 (PGE2), leads to a diminution of the peripheral inflammatory response and a reduction in the chemical sensitization of peripheral nociceptors (pain-sensing nerve endings).

---

Supporting Neuro-Metabolic Integrity

The thiamine (Vitamin B1) component defines a distinct mechanistic domain focused on neuronal metabolism. Thiamine is the precursor to an essential coenzyme, Thiamine Pyrophosphate, which is required for critical enzymes (e.g., Pyruvate Dehydrogenase) in the cellular energy production pathways of nerve cells. By contributing to this necessary cofactor pool, the component influences metabolic activity and supports the high energy demand required for maintaining nerve cell function.

---

Dual-Mode Physiological Modulation

This is a dual-action mechanism based on the synergy between enzymatic inhibition and metabolic cofactor support. The combination provides a simultaneous action on both inflammatory mediator synthesis and neuronal metabolic integrity. This influences overactive signaling pathways toward a modulated activity state, which contributes to the resulting physiological consequence.

How to Use Фламадекс

Фламадекс (Dexketoprofen trometamol) administration follows protocols designed to ensure the proper use of the medicine, emphasizing the lowest effective dose for the shortest possible duration. The usage pattern varies depending on the chosen route and the patient's clinical profile.

---

Administration Routes and Dosing

This medication is available for oral administration (tablets or granules) and parenteral routes (intramuscular or intravenous injection).

Route	Standard Dose	Maximum Daily Dose	Duration Restriction
Oral	12.5 mg every 4 to 6 hours, or 25 mg every 8 hours.	75 mg	Short-term use only.
Parenteral (IM/IV)	50 mg every 8 to 12 hours.	150 mg	Max. 2 days; switch to oral as soon as possible.

---

Administration Requirements and Adjustments

To optimize its effect, the oral forms are recommended to be taken at least 15 to 30 minutes before meals. Parenteral administration, used for more severe acute pain, may be given as a slow intravenous bolus (over at least 15 seconds) or as a diluted infusion over 10 to 30 minutes.

Dosage adjustments are indicated for specific patient populations. For older adults and individuals with mild renal or hepatic impairment, the maximum total daily dose is reduced to 50 mg. Furthermore, the safety and efficacy of the product have not been established in pediatric patients, and its use in children and adolescents is therefore not recommended.

Research Evidence / Overview of Studies for Фламадекс

This overview summarizes the structure of the clinical research and evidence base for Dexketoprofen trometamol, focusing only on the types of studies, populations, and outcomes examined, without providing clinical advice or making statements about efficacy. The findings described relate to patterns observed in controlled research settings.

---

Evidence for Use in Acute Pain Following Procedures (Postoperative Pain)

Research exploring how symptoms change over time following surgical procedures, such as dental or orthopedic operations, has been studied primarily through short-term Randomized Controlled Trials (RCTs) and subsequent analyses. These studies were applied in contexts involving conditions characterized by fluctuating or episodic manifestations of pain.

Studies monitored several key outcomes, including patient-reported pain intensity scores, patient-reported outcomes describing perceived discomfort, and the time elapsed before patients requested additional pain medication. Short-term data were collected; however, a key research limitation frame is that follow-up durations were limited. Evidence remains limited concerning symptom patterns or recovery outcomes that extend beyond this initial acute phase of treatment.

---

Evidence for Use in Acute Musculoskeletal Symptoms

Research examined symptom patterns in conditions involving periods of heightened discomfort related to the muscles, bones, and joints, such as episodes of acute low back pain or temporary flare-ups of knee pain associated with osteoarthritis. The primary study design was Randomized Controlled Trials (RCTs), where the medicine was evaluated in adult populations.

Studies explored outcomes reflecting daily functioning or activity level, alongside patient-reported outcomes describing perceived discomfort. Findings indicate patterns related to symptomatic changes, which contributes to the understanding of short-term symptom patterns.

However, the evidence is concentrated on research scenarios exploring short-term symptom changes. Consequently, there is limited information for long-term outcomes or the trajectory of symptoms during chronic conditions. The current body of research does not fully characterize outcomes associated with long-term administration.

---

Evidence for Use in Specific Pain Syndromes (Dysmenorrhoea and Renal Colic)

Studies monitored the medicine's application in patients experiencing acute, intense pain from conditions associated with acute or disruptive episodes, specifically primary dysmenorrhoea (menstrual pain) and acute renal colic (kidney stone pain). Research has explored its use, often via injection or single oral dose, in settings where symptom onset is sudden and intense.

These investigations focused intensely on immediate outcomes describing episodic or acute changes in pain intensity, with measurements often taken within the first hour of administration. Findings describe patterns observed in the studies where symptoms evolved in the observed populations, and these results were measured against placebo or other active pain medications.

---

What Is Still Uncertain About Фламадекс Research

Transparency in the research record highlights specific areas where evidence is limited: there is limited information for long-term outcomes; the acute pain focus means patterns of symptom change over weeks or months are not fully documented. Comparative evidence is lacking against all available non-opioid pain treatments across the full range of pain types and severities. Furthermore, data for certain groups remain insufficient, especially for the very old or those with significant health co-morbidities.

Key Studies & References

1. Comparison of the analgesic efficacy of dexketoprofen trometamol and meperidine HCl in the relief of renal colic
2. Dexketoprofen Rowex 12.5mg film-coated tablets - Summary of Product Characteristics (HPRA)
3. Keral 50 mg/2ml solution for injection/infusion - Summary of Product Characteristics (HPRA)

Common questions about Фламадекс (FAQ)

---

Q: How quickly should I expect Фламадекс to start working?

Pharmacokinetic studies indicate that the maximum concentration of the drug in the bloodstream is typically reached between 15 and 45 minutes after oral administration. This characteristic supports its intended role in the management of sudden or severe pain, as it is rapidly absorbed.

---

Q: Is Фламадекс an over-the-counter medication or prescription only?

This medication is generally available as a prescription-only medicine. The prescription requirement is primarily due to its potency and safety profile, which includes potential cardiovascular and gastrointestinal risks, necessitating medical oversight for safe use.

---

Q: Is Фламадекс considered a strong painkiller?

Фламадекс is classified as a Non-Steroidal Anti-inflammatory Drug (NSAID). Official reports recognize its use as a potent short-term analgesic, meaning it is intended to be highly effective for managing acute pain over a limited period.

---

Q: Is it safe to take Фламадекс with alcohol?

Official safety information advises against the concurrent consumption of alcohol with this medicine. Combining alcohol with NSAIDs like this can significantly increase the risk of serious side effects, particularly severe gastrointestinal bleeding.

---

Q: Does Фламадекс have potential drug interactions with antidepressants?

Official safety information indicates a potential interaction with certain types of antidepressants. Co-administration with Selective Serotonin Reuptake Inhibitors (SSRIs) may increase the risk of gastrointestinal bleeding or ulceration. Therefore, co-administration requires careful medical oversight.

---

Q: Why is Фламадекс sometimes prescribed post-surgery?

Official indications list its use for the short-term symptomatic treatment of moderate to severe acute pain, which includes pain experienced after surgery. The availability of an injectable form supports its use for rapid pain management in a hospital or clinical setting.

---

Q: Is it necessary to take Фламадекс with food?

To help achieve the quickest onset of action for acute pain relief, regulatory guidance suggests taking the tablets on an empty stomach, such as 30 minutes before a meal. Taking it with food will slow down how quickly the medicine is absorbed, although this may help to decrease the risk of stomach side effects for some individuals.

---

Q: How does the body break down and eliminate Фламадекс?

The drug undergoes biotransformation, a process where it is metabolized into inactive substances known as metabolites. These inactive substances are primarily eliminated from the body through excretion in the urine.

---

Q: What happens if I accidentally take two doses of Фламадекс too close together?

Official patient information states that a double dose should not be taken to compensate for a forgotten dose. Dosing too closely together can increase the concentration of the medication in the body, which may heighten the risk of side effects.

---

Q: Can Фламадекс be used for dental pain or inflammation?

The official product indications include the short-term symptomatic treatment of mild to moderate pain, specifying acute dental pain or toothache as covered uses.

---

Q: Can Фламадекс affect my sleep?

Official regulatory data on undesirable effects mentions potential effects on the Central Nervous System. These potential effects may include dizziness, drowsiness, or nervousness, which could indirectly affect the quality of sleep.

---

Q: Can children or teenagers take Фламадекс?

This medicine is contraindicated, meaning it is prohibited, in children and adolescents under 18 years of age. Use in this age group is not recommended because the safety and effectiveness of the medication have not been established in the pediatric population.

---

Q: What should I do if I miss a dose of Фламадекс?

Regulatory guidance suggests that if a dose is missed, the forgotten dose should be skipped entirely. The next dose should then be taken at the regularly scheduled time, and a double dose must not be taken to compensate for the missed one.

---

Q: Are there specific foods or drinks to avoid while taking Фламадекс?

Official safety information advises against alcohol consumption due to the heightened risk of internal bleeding. Additionally, medicines or supplements containing polyvalent cations, such as calcium or iron, or antacids should be separated from this medication by at least four hours.

---

Q: Can people with diabetes take Фламадекс?

Patients with diabetes require careful monitoring if taking this medication. Official documents state that this medicine may increase the dosage requirements for both insulin and oral antidiabetic agents, necessitating close blood glucose monitoring.

---

Q: Does Фламадекс have a coating to protect the stomach?

The medication is supplied as film-coated tablets. While all NSAIDs carry a risk of gastrointestinal issues, taking the tablets with food may help to potentially reduce stomach side effects, although this will delay the onset of the medicine’s action.

---

Q: Is it safe to drive or operate machinery after taking Фламадекс?

Regulatory information indicates that patients should not drive or handle complex machines if they experience side effects like dizziness or drowsiness, as the medicine may slightly affect these abilities.

---

Q: What is the maximum daily dosage for Фламадекс?

The maximum total daily dose for oral administration is established in the official safety documents. For specific patient groups, such as elderly individuals or those with mild liver or kidney impairment, the maximum daily dose is reduced and must be followed as instructed by a healthcare provider.

---

Q: Why would someone need a prescription for Фламадекс?

The drug is associated with specific contraindications and carries risks for serious side effects, particularly affecting the gastrointestinal and cardiovascular systems. The requirement for a prescription ensures that a healthcare professional can assess the patient’s risk profile and adjust the dosage appropriately for safe use.

---

Q: Is Фламадекс addictive or habit-forming?

No, Фламадекс is a non-steroidal anti-inflammatory drug (NSAID), not an opioid or a controlled substance. Official patient information confirms that it is not associated with habit-forming or addictive tendencies.

How to Store and Dispose of Фламадекс?

The storage and handling of Фламадекс (Dexketoprofen trometamol) must adhere strictly to the conditions specified in the official labeling to maintain its stability and effectiveness.

Official Storage Requirements

Requirement	Condition
Temperature	Store at a temperature not exceeding 25, C
Protection	Keep the product in a place protected from light
Packaging	Store in the original pack to ensure protection
Child Safety	Must be kept out of the sight and reach of children

Disposal Guidelines

It is officially mandated not to use the medicine after the expiry date printed on the packaging. Unused or expired Фламадекс should be disposed of according to local pharmaceutical waste regulations; official documents do not contain specific instructions against flushing or throwing it into household waste.